Pediatrix director sells 6,000 shares back to firm

Pediatrix Medical Group, Inc. (MD) director Laura A. Linynsky reported a disposition to the issuer of 6,000 shares of Common Stock on September 10, 2026, at $26.82 per share.

Rhea-AI Filing Summary

Pediatrix Medical Group, Inc. (MD) director Laura A. Linynsky reported a disposition to the issuer of 6,000 shares of Common Stock on September 10, 2026, at $26.82 per share. After this transaction, she directly holds 33,900 shares. No Rule 10b5-1 trading plan is reported for this transaction.

Insider Trade Summary

Disposition: 6,000 shares

Disposition 1 txn

Insider Linynsky Laura A

Role Director

Type	Security	Shares	Price	Value
Disposition	Common Stock	6,000	$26.82	$161K

Holdings After Transaction: Common Stock — 33,900 shares (Direct)

Key Figures

Shares disposed: 6,000 shares Price per share: $26.82 per share Shares held after transaction: 33,900 shares +1 more

4 metrics

Shares disposed 6,000 shares Common Stock disposition to issuer on September 10, 2026

Price per share $26.82 per share Reported for the 6,000-share disposition on September 10, 2026

Shares held after transaction 33,900 shares Direct Common Stock holdings of Laura A. Linynsky after the disposition

Number of dispose transactions 1 transaction Dispose-type non-derivative transaction reported in this Form 4

Key Terms

Disposition to issuer, Rule 10b5-1, Common Stock

3 terms

Disposition to issuer financial

"classified as a disposition to the issuer involving 6,000 shares"

Rule 10b5-1 regulatory

"the Rule 10b5-1 checkbox is not checked"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

Common Stock financial

"6,000 shares of Common Stock on September 10, 2026"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MD director Laura A. Linynsky report?

Laura A. Linynsky reported a disposition to the issuer of 6,000 shares of Pediatrix Medical Group Common Stock on September 10, 2026, categorized as a disposition to the issuer rather than an open-market sale.

At what price were the Pediatrix Medical Group (MD) shares disposed of?

The 6,000 Pediatrix Medical Group (MD) shares were reported as disposed of at a price of $26.82 per share, with the price stated on a per-share basis for this transaction.

How many Pediatrix Medical Group (MD) shares does the director hold after this Form 4 transaction?

Following the reported disposition, Laura A. Linynsky directly holds 33,900 shares of Pediatrix Medical Group Common Stock, as shown in the post-transaction holdings field of the filing.

Was the MD insider transaction made under a Rule 10b5-1 trading plan?

No. The filing indicates that the Rule 10b5-1 checkbox is not checked, so this reported disposition of 6,000 shares was not affirmed as being made pursuant to a Rule 10b5-1 trading plan.

What type of transaction is reported in this Pediatrix Medical Group (MD) Form 4?

The Form 4 reports a non-derivative transaction in Common Stock, classified as a disposition to the issuer involving 6,000 shares, rather than a derivative exercise, gift, or open-market trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 05:04 PM Accepted by SEC EDGAR 09/14/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Linynsky Laura A

(Last) (First) (Middle)

1301 CONCORD TERRACE

(Street)

SUNRISE FLORIDA 33323

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pediatrix Medical Group, Inc. [ MD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/10/2026		D		6,000	D	$26.82	33,900	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ David Haddock, Attorney-in-Fact	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)